020 8712 5565

Login

Health Conditions

Early Detection Saves Lives: Introducing the Stockholm3 Test at Avicenna Health

As of January 2026, prostate cancer has officially become the most prevalent cancer in the UK. With over 64,000 men diagnosed in 2022, a staggering 21% increase from the previous year. The need for precise, early detection has never been more urgent.

At Avicenna Health, we believe that while we cannot always prevent the incidence of cancer, we can change the outcome. When caught at Stage 1 or Stage 2, prostate cancer survival rates are now close to 100%.

To help our patients access the best possible care, we are proud to offer the Stockholm3 test, a revolutionary leap forward in prostate cancer screening.

Why the Standard PSA Test Isn’t Enough

For decades, the Prostate-Specific Antigen (PSA) blood test has been the standard. However, PSA levels can be misleading:

  • The “False Negative” Gap: If your PSA is between 1.5 – 3.0 ng/ml, it is technically considered “negative.” Yet, evidence suggests that 30–50% of all clinically significant prostate cancers are found in men within this range.
  • The “False Positive” Problem: If your PSA is between 3.0 – 20 ng/ml, it is considered “positive,” but 80% of these cases are false positives, often leading to unnecessary, invasive biopsies and anxiety.

What is Stockholm3?

Stockholm3 is a validated blood test that goes beyond a simple protein count. It uses an advanced algorithm to combine genetic markers, proteins, and clinical data to predict the risk of aggressive prostate cancer.

Key Benefits:

  • Precision: It identifies aggressive cancers even in men with “low” PSA levels (1.5 – 3 ng/ml) who would typically be missed.
  • Reduces Overdiagnosis: It helps men with elevated PSA levels avoid unnecessary imaging or biopsies if their Stockholm3 score is low.
  • Inclusive: The test performs equally well across diverse ethnicities, ensuring reliable results for all men.
  • Proven Results: A landmark 9-year study published in European Urology showed that men with a positive Stockholm3 test were nine times more likely to have high-risk recurrence than those relying on PSA alone.

Our Prostate Screening Offer

Avicenna Health is committed to making advanced screening accessible. We are offering a streamlined testing process:

  1. The Initial Test: We run your PSA test. This involves a blood test and our phlebotomist will come to your home if you live within 4 miles of the clinic or you can have this tested at the clinic if you liver further afield.
  2. Automatic Escalation: If your PSA is greater than 1.5 ng/ml, the Stockholm3 test will automatically be performed on the same sample to ensure no significant disease is missed.
  3. Transparent Pricing: We charge £500 for the combined PSA and Stockholm3 testing.
    • Note: If your PSA is less than 1.5 ng/ml, the Stockholm3 test is not required, and you will be refunded £425 but you will have your PSA result.

Who is eligible?

This test is designed for men aged 45–74 who have no previous diagnosis of prostate cancer.

How to Get Started

If you would like to proceed with testing at Avicenna Health, please do the following:

  1. Registration: Complete our new patient form (if you haven’t visited us before) – New Patient Registration
  2. Respond back to this email with:– Medical History: Provide details on any family history of prostate cancer.– Previous Procedures: Details of any previous prostate biopsies.– Medication List: Information on any prostate-related medications, such as Tamsulosin, Avodart (Dutasteride), or Proscar (Finasteride).

Early detection is the most powerful tool we have. By choosing Stockholm3, you are choosing a more accurate, data-driven approach to your long-term health.